Compare AERO & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AERO | NKTR |
|---|---|---|
| Founded | 1934 | 1990 |
| Country | Mexico | United States |
| Employees | 17068 | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.2B |
| IPO Year | N/A | 1996 |
| Metric | AERO | NKTR |
|---|---|---|
| Price | $15.19 | $68.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $28.57 | ★ $146.67 |
| AVG Volume (30 Days) | 287.8K | ★ 1.2M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $307,711,000.00 |
| Revenue This Year | $11.85 | N/A |
| Revenue Next Year | $4.57 | N/A |
| P/E Ratio | $7.95 | ★ N/A |
| Revenue Growth | N/A | ★ 86.00 |
| 52 Week Low | $12.26 | $21.02 |
| 52 Week High | $23.05 | $109.00 |
| Indicator | AERO | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 36.13 | 50.64 |
| Support Level | $14.46 | $64.30 |
| Resistance Level | $17.17 | $76.78 |
| Average True Range (ATR) | 0.76 | 4.09 |
| MACD | -0.23 | -0.29 |
| Stochastic Oscillator | 12.85 | 29.42 |
Grupo Aeromexico SAB de CV engages in providing air transport services for passengers, goods, and cargo, as well as loyalty program services, training and management services, franchise systems commercialization, and the management of investment in shares. Its services include passenger and cargo transportation, the Club Premier loyalty program, training, charter services, and other aviation-related activities. The company operates through a single operating segment, air transportation, and its geographical presence includes both domestic and international markets, with the majority of revenue coming from the international market.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.